mobile menu
Basic and clinical science – Incretin therapies: DPP-4 inhibitors
02-Dec-15
Schnell, Prof. O.
New views on incretins
02-Dec-15
Deacon, MD C.F.
New evidence from GLP-1 receptor agonist studies: their role in diabetes care (Archive)
23-Sep-13
Nauck, Prof. M. A.
Clinical experience: how can GLP-1 receptor agonists improve daily life for patients? (Archive)
23-Sep-13
Vilsboll, Dr. T.
From UKPDS to SAVOR: the evolving landscape of CV outcomes studies in type 2 diabetes (Archive)
23-Sep-13
Barnett, Prof. A.
Key findings from the SAVOR study: the effects of saxagliptin (Archive)
23-Sep-13
Darius, Prof. Dr. H.
The potential impact of SAVOR on clinical practice (Archive)
23-Sep-13
Mathieu, Prof. Ch.
Summary (Archive)
23-Sep-13
Nauck, Prof. M. A.
How could we transform treatment in type 2 diabetes: which approach, when and for whom? (Archive)
23-Sep-13
Nauck, Prof. M. A. / Barnett, Prof. A. / Vilsboll, Dr. T. / Hadjadj, Dr. S. / Rossing, Dr. P. / Mannucci, Dr. E. / Darius, Prof. Dr. H. / Mathieu, Prof. Ch.
Interactive session & panel discussion (Archive)
01-Oct-12
Pfeiffer, Prof. A. F. H. / Vora, Prof. J. / Khunti, Prof. K. / Fioretto, Prof. P. / Hadjadj, Dr. S. / Mannucci, Dr. E. / Schumm-Draeger, Prof. P.-M. / Baggio, L.
What can we learn from retrospective cardiovascular outcome studies? (Archive)
01-Oct-12
Mannucci, Dr. E.
Introducing SAVOR, a prospective cardiovascular outcomes study (Archive)
01-Oct-12
Schumm-Draeger, Prof. P.-M.
The clinical profile of incretin-based therapies (Archive)
01-Oct-12
Vora, Prof. J.
Linagliptin: a new alternative in DPP-4 inhibition (Archive)
06-Dec-11
Gallwitz, Prof. J. B.
DPP-4 inhibitors: raising expectations (Archive)
06-Dec-11
Fonseca, MD V.
Is the kidney the ignored heart of type 2 diabetes? (Archive)
06-Dec-11
Cooper, Dr. M.
Potentials for cardioprotection (Archive)
29-Oct-11
Marx, Prof. N.
Visceral adipositas: strategies to counteract (Archive)
29-Oct-11
Ritzel, PD Dr. R.
Impact of declining renal function on treatment choice in diabetes (Archive)
12-Sep-11
Groop, Prof. P.-H.
Setting a course for the future (Archive)
12-Sep-11
Aronson, Dr. R.
Going beyond conventional therapies: an update on DPP-4 inhibition (Archive)
12-Sep-11
Holst, Prof. J. J.
A different DPP-4 inhibitor (Archive)
12-Sep-11
Barnett, Prof. A.
New clinical challenges and new opportunities: recent developments in type 2 diabetes in perspective (Archive)
12-Sep-11
Ceriello, Prof. A.
Saxagliptin: now and beyond (Archive)
12-Sep-11
Jacob, Prof. S.
Overcoming barriers now in successful treatment of type 2 diabetes (Archive)
12-Sep-11
Del Prato, Prof. S.
Why we should be treating to succeed (Archive)
20-Oct-10
Del Prato, Prof. S.
A review of treatment satisfaction and quality of life in people with type 2 diabetes (Archive)
20-Oct-10
de Pablos, Prof. Pedro
Latest insights on incretin-based treatments (Archive)
20-Oct-10
Holst, Prof. J. J.
Reducing daily glucose peaks and valleys for comprehensive glycaemic control: a clinical perspective (Archive)
20-Oct-10
Ceriello, Prof. A.
New data on the emerging role of saxagliptin in type 2 diabetes (Archive)
20-Oct-10
Jacob, Prof. S.
CV benefits of GLP-1 analogues and DPP-IV inhibitors: Fact or myth? (Archive)
10-Apr-10
Tschöpe, Prof. D.
The place of DPP-4 inhibitors in national guidelines – country-specific perspectives (Archive)
29-Sep-09
Barnett, Prof. A. / Charbonnel, Prof. B. / Bornstein, Prof. S. / Bosi, Prof. E.
Achieving targets safely: role of DPP-4 inhibitors (Archive)
29-Sep-09
Barnett, Prof. A.
Clinical overview of saxagliptin (Archive)
29-Sep-09
Rosenstock, MD J.
Scientific rationale for DPP-4 inhibition (Archive)
29-Sep-09
Holst, Prof. J. J.
The overall burden of type 2 diabetes (Archive)
29-Sep-09
Bailey, Prof. C.
The Incretin Effect in Health and Disease (Archive)
07-Sep-08
Holst, Prof. J. J.
The potential of incretin enhancers in the treatment of type 2 diabetes (Archive)
11-Sep-05
Holst, Prof. J. J.
The importance of glucagon in glycaemic control: emerging evidence from incretin-based intervention (Archive)
11-Sep-05
Cherrington, Prof. A.
Pancreatic islet preservation: vildagliptin (LAF237), a novel incretin enhancer, increases ß-cell function and mass in animal models (Archive)
11-Sep-05
Hughes, Prof. T. E.
Review of safety and efficacy of vildagliptin (LAF237) (Archive)
11-Sep-05
Ahrén, Prof. B.
Early intervention and treatment of impaired glucose metabolism: The mounting evidence (Archive)
11-Sep-05
Zimmet, Prof. P.
Islet Dysfunction in Type 2 Diabetes – The Role of Incretin Hormones (Archive)
13-Apr-05
Holst, Prof. J. J.
Incretin Enhancement in Type 2 Diabetes – A Vision (Archive)
13-Apr-05
Standl, Prof. E.
Obesity: the role of incretin mimetics in the treatment of Type 2 diabetes (Archive)
05-Sep-04
Pi-Sunyer, Prof. X.
Incretin overview: effects of GLP-1 (Archive)
05-Sep-04
Nauck, Prof. M. A.